Target intelligence / Profile preview

Large neutral amino acid transporter 1 (LAT1)

Target
LAT1
Molecular classification
Transporter
01

Overview

The Large neutral amino acid transporter 1 (LAT1), encoded by the SLC7A5 gene, is a sodium-independent, pH-independent transporter that forms a heterodimeric complex with the glycoprotein CD98 (SLC3A2). LAT1 is highly expressed at the blood-brain barrier (BBB) and in various cancers, where it mediates the uptake of essential large neutral amino acids (such as leucine, phenylalanine, and tyrosine) and thyroid hormones. In oncology, LAT1 is significantly upregulated to meet the high metabolic and nutritional demands of rapidly proliferating tumor cells, making it a key therapeutic target. Inhibiting LAT1, such as with the selective inhibitor nanvuranlat (JPH203), deprives cancer cells of essential amino acids, leading to starvation, suppression of the mTORC1 pathway, and apoptosis. Conversely, LAT1's high expression at the BBB is exploited for drug delivery, allowing amino acid-mimetic drugs (e.g., levodopa, gabapentin) and prodrugs to cross into the central nervous system. Additionally, LAT1 is the primary mediator for the uptake of boronophenylalanine (borofalan) in boron neutron capture therapy (BNCT).

Other names
L-type amino acid transporter 1Solute carrier family 7 member 5SLC7A5Large neutral amino acid transport systemsLarge neutral amino acid transporterSystem L amino acid transporter
02

Mechanism of action

Inhibition of amino acid transport (for inhibitors like nanvuranlat) or utilization as a transport substrate to cross biological barriers (for prodrugs and substrates like levodopa, gabapentin, and borofalan)

03

Biological functions

Amino acid transportCell growthProtein synthesismTOR signaling pathway
04

Disease associations

CancerNeurodegenerative diseaseInborn errors of metabolism
05

Safety considerations

Disruption of blood-brain barrier transportSystemic amino acid deprivationPotential neurotoxicityInterference with thyroid hormone transport
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

LAT1 expressionN-acetyltransferase 2 (NAT2) phenotypeSLC7A5 expression

Beyond the preview

Go deeper on Large neutral amino acid transporter 1 (LAT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Large neutral amino acid transporter 1 (LAT1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call